VNOV (VitaNova Life Sciences) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNOV VitaNova Life Sciences Corp VNOV
51 GF Score
Price $1.38
GF Value $5.95
! 1 Warning Sign
View Full Analysis

What is VitaNova Life Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of VitaNova Life Sciences is: No Data: Cannot be evaluated.

VitaNova Life Sciences  (OTCPK:VNOV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

VitaNova Life Sciences Risk Assessment Related Terms

VNOV vs HKPD, COSM, SNYR: Risk Assessment Comparison

For the Medical Distribution subindustry, VitaNova Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VitaNova Life Sciences Risk Assessment vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where VitaNova Life Sciences's Risk Assessment falls into.


VNOV
51GF Score
VitaNova Life Sciences Corp VNOV
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VitaNova Life Sciences (VNOV) Overvalued in 2026?

Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued. The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.

Key valuation signals for VNOV:

  • Risk Assessment:
  • GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VitaNova Life Sciences Business Description

Address 30 E Broadway, Suite 603, New York, NY, USA, 10002
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score

Get the complete analysis for VNOV

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$5.95
GF Value